Remibrutinib Lifecycle Lead @ (April 2024 - August 2025)
VP, Head of Strategy @ (November 2022 - April 2024)
Principal @ Commonwealth Consulting (January 2018 - November 2022)
Senior Director, Global Mktg, Lilly Diabetes, Trulicity, New Product Planning and Brand Development @ Eli Lilly and Company (January 2014 - January 2017)
Senior Director, Global Marketing, Lilly Diabetes, Trulicity and New Product Planning (Portfolio) @ Eli Lilly and Company (January 2011 - January 2014)
Senior Director for Global Diabetes Marketing, New Product Planning @ Eli Lilly and Company (January 2010 - January 2011)
Director of Global Marketing, Dulaglutide (GLP Fc) @ Eli Lilly and Company (January 2006 - January 2010)
Board Member @ IndyHumane (January 2010 - January 2014)
Mary King Education
Harvard Business School
MBA (Business)
1990-1992
Miami University
BS (Finance)
1982-1986
Mary King Skills
Account Planning
Biologics
Biopharmaceuticals
Biotechnology
Business Analytics
Business Planning
Cardiology
Clinical Development
Clinical Trials
Commercialization
Communication
Competitive Intelligence
Cross-functional Team Leadership
Diabetes
Endocrinology
FDA
Forecasting
Global Marketing
Healthcare Industry
High Performance Teams
Hospital Sales
Lifesciences
Managed Care
Market Access
Market Analysis
Market Development
Market Planning
Market Research
Marketing Intelligence
Marketing Management
Marketing Strategy
Medical Devices
Neurology
Pharmaceutical Industry
Pharmaceutical Marketing
Pharmaceutical Sales
Pharmaceuticals
Pharmaceutics
Problem Solving
Product Launch
Relationship Building
Sales Effectiveness
Segmentation
Strategic Thinking
Strategy
Urology
Written Communication
Leadership
Accounting
Business Analysis
Marketing
Cross Functional Team Leadership
Marketing Communications
Dec Alpha
Cardiovascular Disease
GLP
Product Placement
Consulting
Space
Pennsylvania
R&d
Initiation
Differentiation
Advisory Boards
Shares
Financial Systems
Guiding
Competitive Landscape
Insulin
Packaging
Miami
Collaborative
Sales
Promise
Conferences
Pipelines
Strategic Marketing
Adaptive
Cardiac
Safety
Kidney
Asset Allocation
Quality System
Critical Success Factors
Microsoft Excel
Therapeutic Area
Business Administration
Project Planning
Efficacy
Ovation
Responsibility
Golang
Negotiation
Messaging
Obesity
Market Share
Decision Making
Chicago
Recognizing
Financial Reporting
Device Development
Labels
Encompassing
Payer
Country
Self Directed Work Teams
Strategies
Assessment
Design
Branding
Portfolio Management
Business Development
Science
Market
Strategic Planning
Net
Clinical Research
Investments
Patient
Research
Evidence
Networking
Phase
Business Alignment
Reimbursement
Regulators
Brand Development
Pen
Target Identification
Profiles
Endocrine
Templates
Rules
Positioning
Commercial Planning
Linking
Disclosures
Manufacturing
Asset
Retirement
Injectable
Outstanding Leadership
Fibre Channel
Pacemakers
Vascular
Project Leadership
Meetings
Campaigns
Rolling
Summa Cum Laude
Management
Scientific
Archetypes
Context
Risk Management
Simplicity
Product Development
Quotas
Brand Strategy
Disease
Selling
Customer Experience
Partnerships
Medicine
Regulations
Coaching
Phase 2
Cardiovascular
Entry
Commercial Real Estate
Healthcare
Auditing
Boston
Business Case
Indiana
Portfolio
Seamless
Mary King Summary
Mary King, based in United States, is currently a Executive Director, Immunology Portfolio and Pipeline Strategy at Novartis. Mary King brings experience from previous roles at Novartis, Avalere Health, Commonwealth Consulting and Eli Lilly and Company. Mary King holds a 1990 - 1992 MBA in Business @ Harvard Business School. With a robust skill set that includes Account Planning, Biologics, Biopharmaceuticals, Biotechnology, Business Analytics and more. Mary King has 2 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Mary King?
Find contact details for 700 million professionals.